The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis

Annals of Internal Medicine

Volumn 128, Issue 1, 1998, Pages 15-20

  Middeldorp, Saskia ^a   Henkens, Cecilia M A ^b   Koopman, Maria M W ^a   Van Pampus, Elisabeth C M ^c   Hamulyák, Karly ^c   Van Der Meer, Jan ^d   Prins, Martin H ^a   Büller, Harry R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Ziekenhuis Rivierenland   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; COUMARIN ANTICOAGULANT; HEPARIN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLEEDING; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENETIC SCREENING; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PEDIGREE ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0031985328     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-1-199801010-00003     Document Type: Article

References (21)

1. Heijboer H, Brandjes DP, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-6.
2. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-22.
3. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.
4. 506Gln mutation in factor Va [Letter]. Lancet. 1994;343:1361-2.
5. 506 of factor V. Lancet. 1994;343:1535-6.
6. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-6.
7. Rees DS, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-4.
8. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-7.
9. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-7.
10. Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet. 1996;347:1374-5.
11. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-60.
12. Rosendaal FR, Heijboer H. Briët E. Büller HR, Brandjes DP, de Bruin K, et al. Mortality in hereditary antithrombin-III deficiency-1830 to 1989. Lancet. 1991;337:260-2.
13. Allaart CF, Rosendaal FR, Noteboom WM, Briët E. Survival in families with hereditary protein C deficiency, 1820 to 1993. BMJ. 1995;311:910-3.
14. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol. 1996;143:1257-65.
15. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144-52.
16. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993;153:1557-62.
17. Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand. 1983;62:239-43.
18. Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996;125:955-60.
19. Bridey F, Wolff M, Laissy JP, Morin V, Lefebvre M, de Prost D. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives [Letter]. Thromb Haemost. 1995;74:1382.
20. Dahlbäck B. Are we ready for factor V Leiden screening? Lancet. 1996;347: 1346-7.
21. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ. 1996;313:1127-30.